Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - PROGENICS PHARMACEUTICALS INC | ex99_119jul2016.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) July 19, 2016
Progenics Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware
|
000-23143
|
13-3379479
|
||
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
||
|
|
777 Old Saw Mill River Road, Tarrytown, New York
|
10591
|
||
|
(Address of principal executive offices)
|
(Zip Code)
|
|||
|
Registrant's telephone number, including area code (914) 789-2800
|
||||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 8.01.
|
Other Events.
|
On July 19, 2016, Progenics Pharmaceuticals, Inc. (the "Company") and Valeant Pharmaceuticals International, Inc. issued a joint press release announcing the approval by the United States Food and Drug Administration of RELISTOR® Tablets for the treatment of opioid-induced constipation in adults with chronic non-cancer pain. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits
|
Exhibit No.
|
Description
|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
PROGENICS PHARMACEUTICALS, INC.
|
||
|
By:
|
/s/ Patrick Fabbio
|
|
|
Patrick Fabbio
|
||
|
Chief Financial Officer
|
||
|
(Principal Financial and Accounting Officer)
|
||
Date: July 20, 2016